Infinium Pharmachem Limited (NSE:INFINIUM)

Market Cap	3.32B +5.9%
Revenue (ttm)	1.57B -0.2%
Net Income	93.40M -1.7%
EPS	6.07 -11.2%
Shares Out	15.58M
PE Ratio	35.10
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,500
Average Volume	7,525
Open	214.00
Previous Close	208.45
Day's Range	212.95 - 214.00
52-Week Range	189.40 - 337.00
Beta	0.28
RSI	49.91
Earnings Date	May 22, 2026

About Infinium Pharmachem

Infinium Pharmachem Limited engages in the manufacture and supply of iodine, iodine derivatives, and active pharmaceutical ingredients (APIs) in India and internationally. The company provides iodine based molecules/APIs/iodination reaction based bulk drugs. It also offers potassium iodide and iodate, sodium iodide, iodine, povidone iodine, pralidoxime iodide, thymol iodide, and iodoform products. In addition, the company provides contract research and manufacturing services to pharmaceutical and biotech companies for iodine based APIs and inte...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2003
• Employees: 144
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: INFINIUM

Financial Performance

In fiscal year 2025, Infinium Pharmachem's revenue was 1.56 billion, an increase of 14.78% compared to the previous year's 1.36 billion. Earnings were 81.45 million, a decrease of -27.93%.